Showing results (51-60 of 122) with videos related to

Sort By:
Pageof 13
Blood Cancer Journal|January 17, 2019
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cellsWarren Fiskus, Tianyu Cai, Courtney D DiNardo, et al.
Blood|February 24, 2026
Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitorWarren Fiskus, Christopher P Mill, Ghayas C Issa, et al.
Blood Neoplasia|September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Virchows Archiv : an International Journal of Pathology|March 2, 2023
Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variantSiba El Hussein, L Jeffrey Medeiros, Stephen K Gruschkus, et al.
Molecular Cancer Therapeutics|December 19, 2006
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cellsWarren Fiskus, Michael Pranpat, Maria Balasis, et al.
Cancer Research|June 19, 2008
Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasionYonghua Yang, Rehka Rao, Jie Shen, et al.
The Journal of Biological Chemistry|June 13, 2002
Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptorsAsok Mukhopadhyay, Shishir Shishodia, Jill Suttles, et al.
Blood|November 19, 2024
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AMLWarren Fiskus, Christopher P Mill, Prithviraj Bose, et al.
Blood|April 27, 2019
RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Molecular Cancer Therapeutics|September 20, 2005
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824Liwei Chen, Songshu Meng, Hai Wang, et al.
Pageof 13